Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutaflor (Escherichia coli strain Nissle 1917) in irritable bowel syndrome
DRKS00000416Phase 4Completed
- Sponsor
- Ardeypharm
- Start
- May 2010
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Mutaflor with Placebo (2 arms). Started May 2010; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on DRKS00000416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000416.